Universal Biosensors (ASX:UBI) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

UBI Panoramica delle azioni

UBI analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Analisi del rischio

Gli utili sono diminuiti del 35.7% all'anno negli ultimi 5 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Non ha una capitalizzazione di mercato significativa ( A$42M )

Non ha entrate significative ( A$7M )

Universal Biosensors, Inc. Concorrenti

Compumedics

ASX:CMP

AU$58.8m

Nova Eye Medical

ASX:EYE

AU$55.0m

CurveBeam AI

ASX:CVB

AU$67.4m

Resonance Health

ASX:RHT

AU$27.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Universal Biosensors
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.14
Massimo di 52 settimane	AU$0.30
Minimo di 52 settimane	AU$0.12
Beta	0.93
1Variazione di 1 mese	0%
Variazione a 3 mesi	3.70%
Variazione di 1 anno	-46.15%
3Variazione a 3 anni	-82.05%
Variazione a 5 anni	-34.88%
Variazione dall'IPO	-86.00%

Notizie e aggiornamenti recenti

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15

Rendimenti per gli azionisti

	UBI	AU Medical Equipment	AU Mercato
7D	0%	-6.2%	2.2%
1Y	-46.2%	11.3%	11.2%

Ritorno vs Industria: UBI ha avuto una performance inferiore rispetto al Australian Medical Equipment che ha registrato un rendimento 11.3 % nell'ultimo anno.

Rendimento vs Mercato: UBI ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 11.2 % nell'ultimo anno.

Volatilità dei prezzi

Is UBI's price volatile compared to industry and market?
UBI volatility
UBI Average Weekly Movement	9.0%
Medical Equipment Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: UBI non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di UBI è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2001	80	John Sharman	www.universalbiosensors.com

Universal Biosensors, Inc. attraverso le sue consociate, progetta e sviluppa celle elettrochimiche (strisce) utilizzate in combinazione con dispositivi point-of-use impiegati nei settori sanitario (point-of-care), enologico, alimentare e agricolo in Australia, America, Europa e a livello internazionale. L'azienda produce e distribuisce strisce per il test di coagulazione Prothrombin Time International Normalized Ratio e i dispositivi medici Xprecia Stride e Xprecia Prime per monitorare l'effetto della terapia anticoagulante warfarin; e i prodotti Sentia per l'analisi del vino, come SO2 libera, acido malico, glucosio, fruttosio, acido totale e acidità titolabile. Offre anche servizi di laboratorio non diagnostici ed esegue servizi di analisi della coagulazione.

Universal Biosensors, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Universal Biosensors con la sua capitalizzazione di mercato?
UBI statistiche fondamentali
Capitalizzazione di mercato	AU$41.73m
Guadagni(TTM)	-AU$11.58m
Ricavi(TTM)	AU$7.13m

5.9x

Rapporto P/S

-3.6x

Rapporto P/E

UBI è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
UBI Conto economico (TTM)
Ricavi	AU$7.13m
Costo del fatturato	AU$2.49m
Profitto lordo	AU$4.64m
Altre spese	AU$16.23m
Guadagni	-AU$11.58m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.039
Margine lordo	65.14%
Margine di profitto netto	-162.50%
Rapporto debito/patrimonio netto	1.2%

Come si è comportato UBI nel lungo periodo?

Vedi performance storica e confronto

UBI Panoramica delle azioni

Premi

Analisi del rischio

Universal Biosensors, Inc. Concorrenti

ASX:CMP

AU$58.8m

ASX:EYE

AU$55.0m

ASX:CVB

AU$67.4m

ASX:RHT

AU$27.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Recent updates

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

New minor risk - Share price stability

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Full year 2022 earnings: EPS and revenues miss analyst expectations

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Non-Executive Chairman recently bought AU$54k worth of stock

Price target increased to AU$1.15

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Price target increased to AU$1.15

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Non-Executive Chairman recently bought AU$56k worth of stock

Consensus revenue estimates fall by 19%

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Consensus revenue estimates fall by 10%

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Price target increased to AU$1.25

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

New 90-day high: AU$0.54

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic

New 90-day high - AU$0.33

New 90-day high - AU$0.27